Zacks Investment Research·6d ago
4 Biotech Stocks to Watch as Potential Takeover TargetsBiotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
BioCryst's revenue growth is accelerating, with Q2 2026 revenue up 33.6% sequentially to $218.2M, driven by Orladeyo uptake. Gross margins remain above 98%, and operating leverage has expanded operating margin to 45.1% in Q2 2026 from -15.6% in Q1 2024. Howeve...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 5, 2026 | $0.30+94.6% vs $0.15 | $218M+19.1% vs $183M |
Q2 2026 May 6, 2026 | -$2.98-5066.7% vs $0.06 | $156M+3.5% vs $151M |
Q1 2026 Feb 26, 2026 | $1.12+1500.0% vs $0.07 | $407M+168.7% vs $151M |
Q4 2025 Nov 3, 2025 | $0.06-14.3% vs $0.07 | $159M+5.3% vs $151M |
Biotech M&A surges in 2026, putting ABVX, IOVA, VKTX and BCRX on watchlists, as drugmakers seek late-stage and commercial assets.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations declined from $465.7 million at the end of Q4 2025 to $426.8 million at the end of June.
Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug market.
Benchmark BCRX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for BioCryst Pharmaceuticals, Inc. (BCRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.57 | $2.18B | 7.08 | 94.1% | 30.16% | — | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $25.43 | $4.35B | 11.10 | 11.87% | 33.42% | 32.39% | — | |
| $62.34 | $5.17B | 8.01 | 114.51% | -3.8% | — | — | |
| $115.47 | $9.5B | -31.29 | -16.72% | -285.41% | -21.5% | — |
BioCryst Pharmaceuticals, Inc. (BCRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
BioCryst Pharmaceuticals, Inc. (BCRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 29, 2026·SEC
Jun 12, 2026·SEC
Get notified when BCRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BioCryst Pharmaceuticals, Inc. (BCRX) stock FAQ — growth, dividends, profitability & financials explained
BioCryst Pharmaceuticals, Inc. (BCRX) reported $940.6M in revenue for fiscal year 2025. This represents a 34738% increase from $2.7M in 1996.
BioCryst Pharmaceuticals, Inc. (BCRX) grew revenue by 94.1% over the past year. This is strong growth.
BioCryst Pharmaceuticals, Inc. (BCRX) reported a net loss of $384.7M for fiscal year 2025.
BioCryst Pharmaceuticals, Inc. (BCRX) generated $357.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
